Partnership struck to aid bio manufacturers
![](/46/pdcnewsitem/07/40/70/black-and-white-connect-hand-164531.jpg)
Pall and BioSciencesCorp unite to provide "total solutions" for today's drug manufacturers.
Pall Corporation and BioSciencesCorp have signed a partnership agreement, which will see them deliver cost-effective manufacturing strategies, and efficient upstream and downstream process equipment and facility design solutions for manufacturers.
“We are excited to partner with BioSciencesCorp to provide enabling technologies and services that support their customers' mission-critical projects,” said Mario Philips, VP & General Manager at Pall Biotech. “Together, we can provide total solutions that today’s drug manufacturers need and make an impact where it matters most: with the patient.”
Leveraging deep industry expertise, the BioSciencesCorp team aligns with customers at all phases of the process from concept to commercialization. Customers benefit from small-company style, speed, and service and support from the initial modeling phases through implementation. The team is also available to help with critical aspects of process integrity, such as quality by design, process analytic technologies, and regulatory guidance.
“Starting from feasibility phases through to transfer and training activities, BioSciencesCorp was built to offer quality guidance and support to each customer,” said Daniel Chang, Executive Director and Founder of BioSciencesCorp. “Aligning with Pall Biotech deepens our ability to provide truly end-to-end, integrated solutions to customers from consultation through to clinical development and commercial manufacturing.”
This strategic partnership provides drug manufacturers with direct access to Pall Biotech bioreactors, mixing and storage product lines, single-use downstream technologies, consumables, and inter-unit operation connections. Regardless of the type of project, customers also have the option to work with Pall service teams throughout process design and development to ensure process success.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance